Article
NAT2 phenotype alters pharmacokinetics of rivaroxaban in healthy volunteers.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie - 1 Sept 2023
Villapalos-García Gonzalo, Zubiaur Pablo, Ochoa Dolores, Soria-Chacartegui Paula, Navares-Gómez Marcos, Matas Miriam, Mejía-Abril Gina, Casajús-Rey Ana, Campodónico Diana, Román Manuel, Martín-Vílchez Samuel, Candau-Ramos Carmen, Aldama-Martín Marina, Abad-Santos Francisco
Abstract excerpt
Rivaroxaban is a direct inhibitor of factor Xa, a member of direct oral anticoagulant group of drugs (DOACs). Despite being a widely extended alternative to vitamin K antagonists (i.e., acenocoumarol, warfarin) the interindividual variability of DOACs is significant, and may be related to adverse drug reaction occurrence or drug inefficacy, namely hemorrhagic or thromboembolic events. Since there is not a...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.